Sjögren autoantibodies modify neonatal cardiac function via M1 muscarinic acetylcholine receptor activation.
Isolated congenital heart block may be associated with primary Sjögren syndrome. In this work we describe circulating antibodies in the sera of primary Sjögren syndrome patients that are able to interact with neonatal myocardium by activating muscarinic acetylcholine receptors of M1 subtype. We report on the presence of autoantibodies against the second extracellular loop of human M1 muscarinic acetylcholine receptors in primary Sjögren syndrome mothers whose children have congenital heart block using a synthetic peptide in indirect immunofluorescence technique. Autoantibodies from primary Sjögren syndrome patients gave positive image on neonatal atria but not on adult atria slices. The synthetic M1 peptide selectively abrogated indirect immunofluorescence recognition. The primary Sjögren syndrome-immunoglobulin G also displayed an 'agonist like' activity modifying the intracellular events associated with muscarinic acetylcholine receptor activation. The mechanism appears to occur secondarily to stimulation of phosphoinositides turnover via phospholipase C activation. This, in turn, triggers cascade reactions involving calcium/calmodulin and leads to activation of nitric oxide synthase and soluble guanylate cyclase. All of these effects were selectively blunted by pirenzepine and neutralized by M1 synthetic peptide. These biological effects were not obtained using adult instead of neonatal rat atria and neither occurred with the sera of normal healthy women of childbearing age. It could be concluded that antibodies against neonatal M1 muscarinic acetylcholine receptor may be another serum factor to be considered in the pathophysiology of the development of congenital heart block associated with primary Sjögren syndrome mothers.
Borda
E
E
School of Dentistry and Medicine, University of Buenos Aires and CEFYBO-CONICET, Argentina.
Leiros
C P
CP
Bacman
S
S
Berra
A
A
Sterin-Borda
L
L
D000328:Adult; D000818:Animals; D000831:Animals, Newborn; D001323:Autoantibodies / Q000502:physiology*; D006152:Cyclic GMP / Q000032:analysis; D005260:Female; D019084:Fluorescent Antibody Technique, Indirect; D006325:Heart Atria / Q000503:physiopathology*; D006327:Heart Block / Q000151:congenital* / Q000503:physiopathology*; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D007231:Infant, Newborn; D007295:Inositol Phosphates / Q000032:analysis; D019001:Nitric Oxide Synthase / Q000032:analysis; D011247:Pregnancy; D011248:Pregnancy Complications / Q000276:immunology*; D051381:Rats; D011976:Receptors, Muscarinic / Q000502:physiology*; D012859:Sjogren's Syndrome / Q000276:immunology* / Q000503:physiopathology
D001323:Autoantibodies; D007074:Immunoglobulin G; D007295:Inositol Phosphates; D011976:Receptors, Muscarinic; D019001:Nitric Oxide Synthase; D006152:Cyclic GMP